4.5 hours: The new time window for tissue plasminogen activator in stroke

Stroke

Volumn 40, Issue 6, 2009, Pages 2266-2267

  Davis, Stephen M ^a   Donnan, Geoffrey A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antiplatelet agents; Antiplatelet RX; Therapy

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT;

ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG INDICATION; FIBRINOLYTIC THERAPY; HUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; TIME; ACUTE DISEASE; BRAIN HEMORRHAGE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STANDARD; STATISTICS; STROKE;

ACUTE DISEASE; CEREBRAL HEMORRHAGE; CLINICAL TRIALS, PHASE III AS TOPIC; FIBRINOLYTIC AGENTS; GUIDELINES AS TOPIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 66849142360     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.544171     Document Type: Article

References (12)

1. NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333: 1581-1587.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363: 768-774.
4. Ingall TJ, O'Fallon WM, Asplund K, Goldfrank LR, Hertzberg VS, Louis TA, Christianson TJ. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 2004;35:2418-2424.
5. Wahlgren N, Ahmed N, Davalos A, Hacke W, Millán M, Muir K, Roine RO, Toni D, Lees KR; SITS Investigators. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372:1303-1309.
6. Whiteley W, Lindley R, Wardlaw J, Sandercock P. Third international stroke trial. Int J Stroke 2006;1:172-176.
7. Hoffman JR, Cooper RJ. Stroke thrombolysis: we need new data, not more reviews. Lancet Neurol. 2005;4:204-205.
8. Darby DG, Barber PA, Gerraty RP, Desmond PM, Yang Q, Parsons M, Li T, Tress BM, Davis SM. Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI. Stroke 1999;30:2043-2052.
9. Barber PA, Darby DG, Desmond PM, Yang Q, Gerraty RP, Jolley D, Donnan GA, Tress BM, Davis SM. Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI. Neurology. 1998;51: 418-426.
10. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, BarberPA, BladinC, DeSilvaDA, ByrnesG, ChalkJB, FinkJN, Kimber TE, Schultz D, Hand PJ, Frayne J, Hankey G, Muir K, Gerraty R, Tress BM, Desmond PM; EPITHET investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008; 7:299-309.
11. Khatri P, Hill MD, Palesch YY, Spilker J, Jauch EC, Carrozzella JA, Demchuk AM, Martin R, Mauldin P, Dillon C, Ryckborst KJ, Janis S, Tomsick TA, Broderick JP; Interventional Management of Stroke III Investigators. Methodology of the Interventional Management of Stroke III Trial. Int J Stroke 2008;3:130-137.
12. Saver JL. Time is brain-quantified. Stroke 2006;37:263-266.